Drug intelligence / Profile preview

MWTx 04

Development stage: Preclinical
Lead developer: Mabwell Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

MWTX-04 is a fully human monoclonal antibody developed by Mabwell Therapeutics that selectively targets Muscle-specific kinase (MuSK). MuSK is a receptor tyrosine kinase critical for the formation and maintenance of the neuromuscular junction (NMJ). By precision-targeting MuSK, MWTX-04 aims to enhance efficacy and reduce off-target effects compared to systemic treatments for muscle diseases. The drug is currently in preclinical development, with lead candidates being evaluated in animal models for indications such as muscle atrophy and dystrophy.

Other names: MWTX-04MWTX04MWTX 04

Targets

MUSK (Muscle skeletal receptor tyrosine-protein kinase MuSK)

Beyond the preview

Go deeper on MWTx 04.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MWTx 04.

Explore the full profile